AllSci News
Acoramidis shows signs of cardiac remodeling reversal in ATTR-CM CMR analysis
Serial cardiac magnetic resonance imaging (CMR) data from the Phase III ATTRibute-CM trial and its open-label extension (OLE) now show that acoramidis...
FDA approves Takeda's Mimrylo as first hepcidin mimetic for polycythemia vera
The US FDA has approved Mimrylo (rusfertide), the first hepcidin mimetic peptide cleared for polycythemia vera (PV), giving Takeda (NYSE: TAK) a...
Vutrisiran shows consistent HELIOS-B benefit regardless of tafamidis use
New subgroup data from the HELIOS-B Phase III trial show that vutrisiran (Amvuttra) maintained consistent reductions in all-cause mortality and recurrent...
Five-year Camzyos data show sustained oHCM benefit as aficamten competition emerges
Five-year data from the EXPLORER-LTE cohort of the MAVA-LTE study, presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, show that...
Bayer’s evuzamitide posts 94% sensitivity in Phase III cardiac amyloidosis study
Detailed results from the Phase III REVEAL study evaluating Bayer's iodine 124 evuzamitide as a PET diagnostic for cardiac amyloidosis met both primary...
Leios hands Greater China rights to Phase III fat reduction drug to CMS
La Jolla, California-based Leios Therapeutics has signed an exclusive licensing agreement granting subsidiaries of China Medical System Holdings Limited...
Daiichi Sankyo advances AAX Biotech’s Opti-mAb into antibody program
Sweden-based AAX Biotech AB and Daiichi Sankyo (TSE: 4568) have advanced their research collaboration into an active antibody program following a successful...
BioMarin lands 20% Yuviwel royalty in Ascendis patent settlement
A patent dispute that spanned multiple continents and two of the most closely watched rare disease drugs has ended with BioMarin Pharmaceutical Inc....
Osivax and GC Biopharma combine T-cell and antibody approaches in single-shot flu vaccine
France-based Osivax and South Korea-based GC Biopharma (006280.KS) announced a long-term influenza vaccine collaboration to co-develop and commercialize a...
FDA approves Lisraya as first targeted therapy for dermatomyositis
The US FDA has approved Lisraya (brepocitinib) 30 mg for the treatment of adults with dermatomyositis, making it the first targeted therapy approved for the...
HutchMed’s Atled wins China approval for FGFR2-driven bile duct cancer
China's NMPA has conditionally approved Atled (fanregratinib), an oral selective fibroblast growth factor receptor (FGFR) 1/2/3 inhibitor developed by...
Samsung Biologics raises USD 2.2b to fund PolyPeptide acquisition and capacity expansion
South Korea-based Samsung Biologics (KRX: 207940.KS) announced a rights offering to raise KRW 3 trillion (approximately USD 2.2 billion), with the bulk of...
Pfizer and BioNTech's XFG-adapted Comirnaty given FDA clearance for fall 2026 rollout
The US FDA has approved a supplemental Biologics License Application (sBLA) for Comirnaty XFG (COVID-19 vaccine, mRNA), the 2026–2027 XFG-adapted...
AusperBio raises USD 120m Series C for late-stage hepatitis B antisense therapy
AusperBio Therapeutics, a biopharmaceutical company focused on oligonucleotide therapies for chronic hepatitis B (CHB), has closed a USD 120 million Series...
FDA approves Gilead's Bixlenvo to simplify complex HIV regimens
The US FDA has approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single-tablet regimen (STR) for HIV-1 treatment in virologically...
The AllSci Brief
Free, systematic R&D and deal news. Daily.